Centralized MR-guided brachytherapy maintained 95% local control in cervical cancer
Nationwide referral to one MR-IGABT centre kept median treatment time at 50 days and achieved 95% 3-year local control.
Nationwide referral to one MR-IGABT centre kept median treatment time at 50 days and achieved 95% 3-year local control.
TIMELESS scaffolded SIRT1-mediated Ku70 deacetylation, enhanced NHEJ repair and increased radioresistance in cervical cancer cells and xenografts.
Compressing three HDR brachytherapy fractions into one week shortened overall treatment time and increased early complete response without improving survival.
Random forest best predicted ovarian dose after transposition, but all models deteriorated sharply when ovaries lay within approximately 17 mm of the PTV.
Routine CT-based adaptive brachytherapy achieved 84.4% five-year local control despite 56.9% of patients having stage III–IV cervical cancer.
Median survival was 25 versus 18 months with chemotherapy plus definitive pelvic radiotherapy after propensity matching in stage IVB cervical cancer.
Sexual inactivity reached 49% and dyspareunia 54% after cervical radio(chemo)therapy, with fatigue central to broader survivorship impairment.
Adding DWI/ADC produced substantially different residual GTV geometry before cervical brachytherapy, with a median Dice overlap of only 0.33.
Combined radiomics, foundation-model and clinical features predicted grade ≥2 radiation proctitis with 0.865 AUC on an independent imaging device.
Cervical cancer stage progression was estimated every 8.6 weeks of treatment delay and was faster among women living with HIV.
Low CAVIN3 expression was associated with higher treatment response and substantially longer progression-free survival after radiotherapy for cervical cancer.
Task-specific deep learning halved pelvic artifact burden, improved applicator reconstruction to 0.1 mm, and shortened organ contouring by up to 40%.
Nine-field intensity-modulated radiotherapy shortened overall planning-plus-delivery time and improved several pelvic dose metrics compared with volumetric modulated arc therapy.
Daily online adaptation improved pelvic target coverage during 17-fraction cervical chemoradiotherapy, with 10% grade ≥3 gastrointestinal toxicity.
Retroverted uterine position increased rectal and bowel dose during cervical brachytherapy, but survival, recurrence and severe toxicity remained comparable.